Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
09:20am, Monday, 30'th Sep 2024
Responder Analyses Show Treatment with Aficamten Demonstrated Improvements on Multiple Assessments of Clinical Significance to Cardiologists
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
11:00am, Friday, 27'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Unde
Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
07:30am, Tuesday, 24'th Sep 2024
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular Diseases
Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
04:00pm, Thursday, 19'th Sep 2024
Analyses of Effects of Aficamten on Key Clinical Outcomes from SEQUOIA-HCM to be Featured in Late Breaking Clinical Trial Presentation at HFSA
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
09:22am, Thursday, 19'th Sep 2024
Edgewise Therapeutics stock skyrocketed on Thursday after a single dose of its drug improved heart function in cardiomyopathy patients.
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
01:11pm, Monday, 09'th Sep 2024
Monday, Cytokinetics, Incorporated CYTK announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology Annual M
Cytokinetics Announces Data From Phase 1 Study of CK-4021586
07:30am, Monday, 09'th Sep 2024
Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
04:00pm, Thursday, 05'th Sep 2024
Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024 Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Wednesday, 04'th Sep 2024
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 30, 2024 it granted stock options to purchase an aggregate of 5
Data from Integrated Safety Analysis Across Three Clinical Trials Reinforces Robust Safety Profile of Aficamten
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
03:51am, Sunday, 01'st Sep 2024
Additional Data from SEQUOIA-HCM Demonstrate Favorable Cardiac Remodeling by Cardiac MRI, Improvements in Cardiac Structure and Function by Echocardiography, Symptom Relief and Improvement in Biomarke
Cytokinetics to Participate in September Investor Conferences
04:00pm, Thursday, 29'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferen
Cytokinetics, Incorporated (CYTK) Q2 2024 Earnings Call Transcript
09:17pm, Friday, 09'th Aug 2024
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Diane Weiser - VP, Corporate Affairs Robert Blum - President, CEO Fady Malik -
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
11:21am, Friday, 09'th Aug 2024
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
06:11pm, Thursday, 08'th Aug 2024
Cytokinetics (CYTK) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.34 per share a year ago.
